Veeda Oncology selects TrialWorks by ClinPhone to further strengthen clinical trial management capabilities.
Nottingham, UK-May 19, 2008-ClinPhone (www.clinphone.com), a major Clinical Technology Organization (CTO), announces that Veeda Oncology, a specialist CRO, has selected TrialWorks by ClinPhone to further strengthen its clinical trial management capabilities.
Veeda Oncology (www.veedaoncology.com), a subsidiary of Veeda Clinical Research, will implement TrialWorks across its four major sites in India, France, Germany, and the US, providing international team members with real-time, immediate access to the company’s clinical trial management data and reports.
Speaking about the selection of TrialWorks, Kathy Squillace, vice president of global clinical operations at Veeda Oncology, stated, “One of our primary goals when establishing Veeda Oncology was to ensure we had a state-of-the-art infrastructure in place to effectively track, manage and report on our clinical data globally. Because our sites are spread geographically, we needed a web-based system that was intuitive and easy to use, while still offering robust functionality. TrialWorks emerged as the leader for us in this regard.”
Veeda Oncology had initially approached ten vendors, of which three matched their full user requirements. As well as the competitive price, it was the user interface and monitoring module that appealed to Veeda Oncology and ultimately led to their selection of TrialWorks. The monitoring module permits monitors to upload data remotely and produce monitoring reports in Microsoft Word format. TrialWorks, which is a web-based hosted or licensed solution, has strong functionality and is well-known for being very user-friendly and intuitive.
Squillace also added, “We’re confident that TrialWorks will not only save time for our monitors and site personnel, but will also provide significant support to our project managers, particularly in areas such as the tracking and management of investigator payments.”
TrialWorks is a powerful, user-friendly application designed to track, manage and report on virtually all day-to-day study management information. TrialWorks provides comprehensive trial management data, ranging from high-level consolidated metrics for senior managers to meaningful, drill-down reports to support project teams. The underlying relational database allows information to be grouped and filtered at various levels including trial, country, and site/investigator.
Ian Jennings, senior vice president of business development at ClinPhone, commented, “TrialWorks is a proven solution and has been used for thousands of trials by companies around the world. By implementing TrialWorks across Veeda Oncology sites and providing unrivaled customer service and support, we aim to offer the benefits of easier, faster and more efficient clinical trial management.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.